Anti-psychotic drug reduction in primary care for adults with learning disabilities

Not Applicable

Completed

• Conditions: earning disabilities; Mental and Behavioural Disorders; Developmental disorder of scholastic skills, unspecified

• Registration Number: ISRCTN38126962
• Lead Sponsor: Cardiff University (UK)

Brief Summary

2017 results in: https://www.ncbi.nlm.nih.gov/pubmed/28857740

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-04-08
• Study Completion: 2016-06-30
• Last Update Posted: 27 August 2018

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 310

Inclusion Criteria

1. Aged 18 or over
2. Have a learning disability as judged by administrative classification (e.g. on practice learning disability register, in receipt of an annual learning disability health check, in receipt of learning disability services) and a score on the Adaptive Behaviour Scale that converts to an estimated IQ of 70 or below using the method described by Moss and Hogg
3. Currently prescribed one of two anti-psychotic drugs, haloperidol or risperidone, for treatment of challenging behaviour

Exclusion Criteria

1. Current diagnosis of psychosis
2. Known recurrence of psychosis following previous drug reduction in the past 3 years
3. The clinician responsible for their treatment judges for any other reason that the participation in a drug reduction programme may be counter-indicated.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Aggression, evaluated using the Modified Overt Aggression Scale (MOAS). The MOAS rates four categories of aggression (verbal aggression, destruction of property, self-mutilation and physical aggression to others) measured at baseline, 6 months, 9 months and 12 months.

Secondary Outcome Measures

Name	Time	Method
1. Adaptive behaviour, measured using the Adaptive Behaviour Scale (ABS) at screening<br>2. Mental health, measured using the Psychiatric Assessment Schedule for Adults with Developmental Disability Checklist (PAS-ADD) at screening, baseline, 6 months, 9 months and 12 months<br>3. Adverse effects of psychotropic medication, measured using the Udvalg for Kliniske Undersøgelser scale (UKU) at baseline and 9 months<br>4. Movement disorders, measured using the Dyskinesia Identification System Condensed User Scale (DISCUS) at baseline and 9 months<br>5. Other challenging behaviour, measured using the Aberrant Behaviour Checklist (ABC) at baseline, 6 months, 9 months and 12 months<br>6. Costs, measured using the Client Service Receipt Inventory [modified] (CSRI) at baseline, 6 months, 9 months and 12 months